AU2020319164A1 - Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment - Google Patents
Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment Download PDFInfo
- Publication number
- AU2020319164A1 AU2020319164A1 AU2020319164A AU2020319164A AU2020319164A1 AU 2020319164 A1 AU2020319164 A1 AU 2020319164A1 AU 2020319164 A AU2020319164 A AU 2020319164A AU 2020319164 A AU2020319164 A AU 2020319164A AU 2020319164 A1 AU2020319164 A1 AU 2020319164A1
- Authority
- AU
- Australia
- Prior art keywords
- sotagliflozin
- patients
- dose
- type
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19188477.4A EP3769767A1 (en) | 2019-07-25 | 2019-07-25 | Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment |
| EP19188477.4 | 2019-07-25 | ||
| PCT/IB2020/057016 WO2021014420A1 (en) | 2019-07-25 | 2020-07-24 | Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020319164A1 true AU2020319164A1 (en) | 2022-02-24 |
Family
ID=67438963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020319164A Abandoned AU2020319164A1 (en) | 2019-07-25 | 2020-07-24 | Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220265690A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3769767A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022541322A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114222571A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020319164A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3148400A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021014420A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008010959A2 (en) | 2006-07-14 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | Beam ablation lithography |
-
2019
- 2019-07-25 EP EP19188477.4A patent/EP3769767A1/en not_active Ceased
-
2020
- 2020-07-24 EP EP20747477.6A patent/EP4003366A1/en not_active Withdrawn
- 2020-07-24 AU AU2020319164A patent/AU2020319164A1/en not_active Abandoned
- 2020-07-24 CA CA3148400A patent/CA3148400A1/en active Pending
- 2020-07-24 WO PCT/IB2020/057016 patent/WO2021014420A1/en not_active Ceased
- 2020-07-24 US US17/629,166 patent/US20220265690A1/en not_active Abandoned
- 2020-07-24 CN CN202080053637.0A patent/CN114222571A/zh not_active Withdrawn
- 2020-07-24 JP JP2022504622A patent/JP2022541322A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3148400A1 (en) | 2021-01-28 |
| CN114222571A (zh) | 2022-03-22 |
| WO2021014420A1 (en) | 2021-01-28 |
| EP4003366A1 (en) | 2022-06-01 |
| US20220265690A1 (en) | 2022-08-25 |
| JP2022541322A (ja) | 2022-09-22 |
| EP3769767A1 (en) | 2021-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240115708A1 (en) | Dosing Regimens For The Treatment Of Fabry Disease | |
| Danne et al. | HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study | |
| Cherney et al. | Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin | |
| Allegaert et al. | Developmental pharmacokinetics in neonates: maturational changes and beyond | |
| AU2012328388A1 (en) | Treatment protocol of diabetes type 2 | |
| Zakaraia et al. | Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial. | |
| Sosale et al. | A prospective analysis of the efficacy and safety of sodium glucose cotransporter 2 inhibitors: real world evidence from clinical practice in India | |
| EP4003366A1 (en) | Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment | |
| Powell et al. | Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management | |
| Karyekar et al. | Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes | |
| Bellomo Damato et al. | Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia | |
| HK40062957A (en) | Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment | |
| JP7482146B2 (ja) | 1型真性糖尿病を有する患者の治療のためのソタグリフロジンの使用 | |
| US20130072454A1 (en) | Anti-diabetic compostions and methods | |
| Sharma | Section 8: Diabetes Care in Special Populations | |
| Gupta | 25 Intensive Glycemic Control: Is it | |
| Bermejo et al. | 4CPS-070 Study of cardiovascular toxicity associated with ibrutinib treatment | |
| Hwang et al. | Dose-dependent glucosuria of DWP16001, a novel selective SGLT-2 inhibitor, in healthy subjects | |
| Mohamad Hosein Zade Davatgari et al. | Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient Treated with Empagliflozin: Case Report | |
| Hosein et al. | Canagliflozin: A First-in-Class Medication for the Treatment of Type 2 Diabetes Mellitus | |
| HK40036814A (en) | Dosing regimens for the treatment of fabry disease | |
| de Souza Faustino et al. | The Benefits of SGLT2 Inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes | |
| NZ615726B2 (en) | Dosing regimens for the treatment of fabry disease | |
| NZ715144A (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| EP4051281A1 (en) | Treatment of diabetic nephropathy with an sgc stimulator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |